Ophthalmology. Retina最新文献

{"title":"Enhanced-Depth Imaging of Optic Disc Infiltration by Breast Carcinoma","authors":"","doi":"10.1016/j.oret.2024.03.015","DOIUrl":"10.1016/j.oret.2024.03.015","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 11","pages":"Page e38"},"PeriodicalIF":4.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140788528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unusual Retinal Hemorrhages in a Highly Myopic Patient","authors":"","doi":"10.1016/j.oret.2024.03.022","DOIUrl":"10.1016/j.oret.2024.03.022","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 11","pages":"Page e40"},"PeriodicalIF":4.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140865427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Real World” Management of Acute-Onset Postoperative Endophthalmitis with Presenting Visual Acuity of Light Perception","authors":"Stephen G. Schwartz MD, MBA - Naples, Florida, Harry W. Flynn Jr. MD - Miami, Florida","doi":"10.1016/j.oret.2024.07.023","DOIUrl":"10.1016/j.oret.2024.07.023","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 11","pages":"Pages 1033-1034"},"PeriodicalIF":4.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genome-wide Meta-analysis for Myopic Macular Neovascularization Identified a Novel Susceptibility Locus and Revealed a Shared Genetic Susceptibility with Age-Related Macular Degeneration.","authors":"Kazuya Morino, Masahiro Miyake, Masao Nagasaki, Takahisa Kawaguchi, Shogo Numa, Yuki Mori, Shota Yasukura, Masahiro Akada, Shin-Ya Nakao, Ai Nakata, Hiroki Hashimoto, Ryoko Otokozawa, Koju Kamoi, Hiroyuki Takahashi, Yasuharu Tabara, Fumihiko Matsuda, Kyoko Ohno-Matsui, Akitaka Tsujikawa","doi":"10.1016/j.oret.2024.09.016","DOIUrl":"10.1016/j.oret.2024.09.016","url":null,"abstract":"<p><strong>Purpose: </strong>To identify the susceptibility loci for myopic macular neovascularization (mMNV) in patients with high myopia.</p><p><strong>Design: </strong>A genome-wide association study (GWAS) meta-analysis (meta-GWAS).</p><p><strong>Participants: </strong>We included 2783 highly myopic individuals, including 608 patients with mMNV and 2175 control participants without mMNV.</p><p><strong>Methods: </strong>We performed a meta-analysis of 3 independent GWASs conducted according to the genotyping platform (Illumina Asian Screening Array [ASA] data set, Illumina Human610 BeadChip [610K] data set, and whole genome sequencing [WGS] data set), adjusted for age, sex, axial length, and the first to third principal components. We used DeltaSVM to evaluate the binding affinity of transcription factors (TFs) to DNA sequences around the susceptibility of single nucleotide polymorphisms (SNPs). In addition, we evaluated the contribution of previously reported age-related macular degeneration (AMD) susceptibility loci.</p><p><strong>Main outcome measures: </strong>The association between SNPs and mMNV in patients with high myopia.</p><p><strong>Results: </strong>The meta-GWAS identified rs56257842 at TEX29- LINC02337 as a novel susceptibility SNP for mMNV (odds ratio [OR]_meta = 0.62, P_meta = 4.63 × 10^-8, I² = 0.00), which was consistently associated with mMNV in all data sets (OR_ASA = 0.59, P_ASA = 1.71 × 10^-4; OR_610K = 0.63, P_610K = 5.53 × 10^-4; OR_WGS = 0.66, P_WGS = 4.38 × 10^-2). Transcription factor-wide analysis showed that the TFs ZNF740 and EGR1 lost their binding affinity to this locus when rs56257842 had the C allele (alternative allele), and the WNT signaling-related TF ZBTB33 gained binding affinity when rs56257842 had the C allele. When we examined the associations of AMD susceptibility loci, rs12720922 at CETP showed a statistically significant association with mMNV (OR_meta = 0.52, P_meta = 1.55 × 10^-5), whereas rs61871745 near ARMS2 showed a marginal association (OR_meta = 1.25, P_meta = 7.79 × 10^-3).</p><p><strong>Conclusions: </strong>Our study identified a novel locus associated with mMNV in high myopia. Subsequent analyses offered important insights into the molecular biology of mMNV, providing the potential therapeutic targets for mMNV. Furthermore, our findings imply shared genetic susceptibility between mMNV and AMD.</p><p><strong>Financial disclosure(s): </strong>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy","authors":"","doi":"10.1016/j.oret.2024.04.023","DOIUrl":"10.1016/j.oret.2024.04.023","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the impact of reduction in geographic atrophy (GA) lesion growth on visual acuity in the GATHER trials using categorical outcome measures.</div></div><div><h3>Design</h3><div>Randomized, double-masked, sham-controlled phase 3 trials.</div></div><div><h3>Participants</h3><div>Aged ≥50 years with noncenter point-involving GA and best-corrected visual acuity (BCVA) of 25 to 80 ETDRS letters in the study eye.</div></div><div><h3>Methods</h3><div>GATHER1 consisted of 2 parts. In part 1, 77 patients were randomized 1:1:1 to avacincaptad pegol (ACP) 1 mg, ACP 2 mg, and sham. In part 2, 209 patients were randomized 1:2:2 to ACP 2 mg, ACP 4 mg, and sham. In GATHER2, patients were randomized 1:1 to ACP 2 mg (n = 225) and sham (n = 223). A post hoc analysis of 12-month data for pooled ACP 2 mg and sham groups is reported.</div></div><div><h3>Main Outcome Measures</h3><div>Proportion of study eyes that experienced ≥10-, ≥15-, or ≥20-BCVA ETDRS letter loss from baseline to month 12; time-to-event analysis of persistent vision loss of ≥10, ≥15, or ≥20 BCVA letters from baseline at ≥2 consecutive visits over 12 months; proportion of study eyes with BCVA loss to a level below driving eligibility threshold at month 12 among those eligible to drive at baseline.</div></div><div><h3>Results</h3><div>Lower proportions of study eyes experienced ≥10-, ≥15-, or ≥20-BCVA letter loss from baseline over 12 months with ACP 2 mg (11.6%, 4.0%, and 1.6%, respectively) versus sham (14.1%, 7.6%, and 4.5%, respectively). There was a reduction in the risk of persistent loss of ≥15 BCVA ETDRS letters with ACP 2 mg (3.4%) versus sham (7.8%) through 12 months. A lower proportion of study eyes treated with ACP 2 mg reached the threshold for driving ineligibility versus sham by 12 months.</div></div><div><h3>Conclusions</h3><div>Treatment with ACP 2 mg delayed the risk of progression to persistent vision loss (i.e., ≥10-, ≥15-, and ≥20-BCVA letter loss or BCVA loss to a level below driving eligibility threshold) versus sham over 12 months.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 11","pages":"Pages 1052-1060"},"PeriodicalIF":4.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preretinal Deposits in a Keratoprosthesis-Associated Bacterial Endophthalmitis","authors":"","doi":"10.1016/j.oret.2024.04.004","DOIUrl":"10.1016/j.oret.2024.04.004","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 11","pages":"Page e42"},"PeriodicalIF":4.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrawidefield Fluorescein Angiography and OCT Findings in Children and Young Adults with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy","authors":"","doi":"10.1016/j.oret.2024.05.010","DOIUrl":"10.1016/j.oret.2024.05.010","url":null,"abstract":"<div><h3>Purpose</h3><div><span><span>Autosomal dominant neovascular inflammatory </span>vitreoretinopathy (ADNIV) is a rare genetic (</span><span><span>CAPN5</span></span><span>) autoimmune condition typically diagnosed in adulthood and characterized by a triad of inflammation, retinal degeneration<span><span>, and neovascularization<span>. We report novel multimodal imaging findings in children and young adults with ADNIV, and early treatment response to short-duration local and </span></span>systemic corticosteroids.</span></span></div></div><div><h3>Design</h3><div>Retrospective consecutive case series.</div></div><div><h3>Participants</h3><div>Ten patients aged &lt;25 years with ADNIV and available multimodal imaging.</div></div><div><h3>Methods</h3><div><span>The medical records of patients aged &lt;25 years with a diagnosis of ADNIV with ultrawidefield </span>fluorescein angiography<span> (UWFFA) and OCT data were reviewed.</span></div></div><div><h3>Main Outcome Measures</h3><div>Ultrawidefield fluorescein angiography and OCT findings at baseline and after local corticosteroids.</div></div><div><h3>Results</h3><div><span>Median age at presentation was 14 years (range, 9–24 years). OCT on presentation demonstrated cystoid macular edema in 8 of 20 eyes and symptomatic vitreoretinal interface disease in 2 of 20 eyes. Initial UWFFA demonstrated retinal vascular leakage (20/20 eyes, 100%), peripheral nonperfusion (13/20 eyes, 65%), and </span>retinal neovascularization (6/20 eyes, 30%). Retinal vascular leakage improved with local corticosteroids, and neovascularization regressed with anti-VEGF therapy.</div></div><div><h3>Conclusions</h3><div>Ultrawidefield fluorescein angiography findings of prefibrotic ADNIV reported in adults were also present in children and young adults. Early testing for a pathogenic <em>CAPN5</em><span> variant in at-risk children and regularly scheduled screening for uveitis<span><span> and retinal vasculitis with UWFFA and OCT may prompt earlier intervention. Short-duration local steroids are effective at treating retinal vascular leakage and </span>macular edema<span> but are not durable, suggesting a potential role for steroid-sparing immunosuppressive therapy. Early treatment may alter the natural history of disease.</span></span></span></div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 11","pages":"Pages 1107-1112"},"PeriodicalIF":4.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141088684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal Infliximab for the Treatment of Proliferative Vitreoretinopathy (FIXER)","authors":"","doi":"10.1016/j.oret.2024.05.016","DOIUrl":"10.1016/j.oret.2024.05.016","url":null,"abstract":"<div><h3>Objective</h3><div><span>To study the safety and efficacy of intravitreal infliximab administered at the conclusion of </span>pars plana vitrectomy<span><span> (PPV) in the treatment of proliferative vitreoretinopathy (PVR) associated with </span>rhegmatogenous retinal detachment (RRD).</span></div></div><div><h3>Design</h3><div>Randomized controlled phase II clinical trial.</div></div><div><h3>Subjects</h3><div>Patients with primary RRD and grade C PVR, according to the updated Retina Society Classification.</div></div><div><h3>Methods</h3><div><span>Sixty-six patients were randomized in a 1:1 ratio to undergo PPV and silicone oil (SO) injection with or without </span>intravitreal injection<span> of 1 mg/0.05 mL of infliximab in the air-filled globe before SO injection at PPV conclusion. Surgeons were masked to treatment allocation until PPV conclusion.</span></div></div><div><h3>Main Outcome Measures</h3><div>The primary outcome measure was anatomic success (defined as complete retinal reattachment without a tamponade at 6 months post SO removal). Secondary outcome measures were final best-corrected visual acuity (BCVA), single-operation success rate (SOSR), rate of recurrent detachment, central macular thickness (CMT) by macular OCT<span>, macular function by multifocal electroretinogram, and macular vascular density (VD) by OCT angiography.</span></div></div><div><h3>Results</h3><div><span><span><span>Sixty eyes of 60 patients, 30 eyes in each group, completed the study. At baseline, there were no differences regarding age, gender, history of trauma, lens status, duration of RRD, BCVA, </span>intraocular pressure (IOP), intraocular inflammation (IOI), detachment extent in clock hours, number/size of breaks, presence of </span>vitreous hemorrhage, axial length, or grade/extent of PVR between both groups. For the outcome measures, 30 eyes in the infliximab group achieved anatomic success vs. 29 eyes in the control group. The SOSR was higher in the infliximab group (26) vs. the control (23), but this was not statistically significant (</span><em>P</em> = 0.317). Final logarithm of the minimum angle of resolution BCVA was better in the infliximab group (mean, 0.96; standard deviation [SD], 0.4; Snellen equivalent ≈ 20/180) vs. the control (mean, 1.14; SD, 0.4); Snellen equivalent ≈ 20/280; <em>P</em> = 0.044). There were no differences regarding IOP, IOI, time of SO removal, macular function, CMT, or VD.</div></div><div><h3>Conclusions</h3><div>Pars plana vitrectomy with SO tamponade with or without intravitreal infliximab is effective in treating PVR-associated RRD. Infliximab may be associated with modest improvement in final visual outcomes but not anatomic outcomes.</div></div><div><h3>Financial Disclosure(s)</h3><div>The authors have no proprietary or commercial interest in any materials discussed in this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 11","pages":"Pages 1044-1051"},"PeriodicalIF":4.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular Albinism with Unilateral Retinochoroidal Coloboma and Retinal Detachment","authors":"","doi":"10.1016/j.oret.2024.04.011","DOIUrl":"10.1016/j.oret.2024.04.011","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 11","pages":"Page e43"},"PeriodicalIF":4.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140912323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iris Flocculus","authors":"","doi":"10.1016/j.oret.2024.03.009","DOIUrl":"10.1016/j.oret.2024.03.009","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"8 11","pages":"Page e37"},"PeriodicalIF":4.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}